Correction: Latacz et al. Safety and Efficacy of Low-Dose Eptifibatide for Tandem Occlusions in Acute Ischemic Stroke. Neurol. Int. 2024, 16, 253–262
Paweł Latacz, Tadeusz Popiela, Paweł Brzegowy, Bartłomiej Lasocha, Krzysztof Kwiecień, Marian Simka
Abstract
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsStroke Rehabilitation and Recovery · Neurological Disorders and Treatments · Acute Ischemic Stroke Management
Text Correction
There was an error in the original publication [1]. A correction has been made to the Introduction. Originally, it stated: “Epifibatide is cleared by the kidneys, and its plasma half-life is about 1.5–2 h. Because of its short half-life, in patients without renal insufficiency, a cessation of epifibatide infusion restores normal hemostatic platelet function within 15–30 min [20].”.
This paragraph should be as follows: “Epifibatide is cleared by the kidneys, and its pharmacokinetic plasma half-life is about 4 h. Because of its short half-life, in patients without renal insufficiency, a cessation of epifibatide infusion relatively quickly restores normal hemostatic platelet function [20]. Its biological half-life is estimated to be at the level of 2.5 h, while the “real-life” stop of a prolonged bleeding, demonstrated in many clinical trials and in every-day hospital practice, is within 30 min.”.
The authors state that the scientific conclusions are unaffected. This correction was approved by the Academic Editor. The original publication has also been updated.
The reference list from the paper itself. Each links out to its DOI / PubMed record.